[HTML][HTML] The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
Association of high tumor mutation burden in non–small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across …
Importance Although tumor mutation burden (TMB) has been explored as a potential
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …
biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus about …
[HTML][HTML] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …
[HTML][HTML] Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
Introduction STK11 and KEAP1 mutations (STK11 mutant [STK11 MUT] and KEAP1 MUT)
are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 …
are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 …
[HTML][HTML] Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
TMB or not TMB as a biomarker: That is the question
Immune checkpoint inhibitors (ICIs) have revolutionized the landscape of therapeutic
options for many cancers. These treatments have demonstrated improved efficacy and often …
options for many cancers. These treatments have demonstrated improved efficacy and often …
Clinicopathologic and genomic factors impacting efficacy of first-line chemoimmunotherapy in advanced NSCLC
Introduction Although programmed cell death protein 1 and programmed death-ligand 1 (PD-
L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of …
L1) blockade in combination with platinum-doublet chemotherapy has become a mainstay of …
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …
blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L) 1 …